
|Articles|February 15, 2004
B&L finishes purchase of new fluoroquinolone
Rochester, NY-Bausch & Lomb has completed the purchase of InSite Vision's ISV-403 compound for the treatment of ocular infections. Bausch & Lomb gave InSite Vision an undisclosed cash sum and reimbursement of certain product development expenses. In exchange, InSite Vision will give Bausch & Lomb a percentage of future product sales in all licensed countries.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
Opuviz aflibercept biosimilar launches in Europe for retinal diseases
4
Study links alcohol consumption to earlier advanced presbyopia in men
5





















